The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells

Cell Death and Disease

Volumn 5, Issue , 2014, Pages

  O'Donnell, E F ^a   Koch, D C ^a   Bisson, W H ^a   Jang, H S ^a   Kolluri, S K ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RALOXIFENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST EPITHELIUM CELL; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CELL VIABILITY; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; DRUG CONFORMATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLUORESCENCE MICROSCOPY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT;

EID: 84907854398     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.549     Document Type: Article

References (57)

1. Beischlag TV, Luis Morales J, Hollingshead BD, Perdew GH. The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 2008; 18: 207-250.
2. Dragan YP, Schrenk D. Animal studies addressing the carcinogenicity of TCDD (or related compounds) with an emphasis on tumour promotion. Food Addit Contam 2000; 17: 289-302.
3. Kociba RJ, Keyes DG, Beyer JE, Carreon RM, Wade CE, Dittenber DA et al. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-Tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 1978; 46: 279-303.
4. Ray S, Swanson HI. Activation of the aryl hydrocarbon receptor by TCDD inhibits senescence: A tumor promoting event? Biochem Pharmacol 2009; 77: 681-688.
5. Viluksela M, Bager Y, Tuomisto JT, Scheu G, Unkila M, Pohjanvirta R et al. Liver tumor-promoting activity of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in TCDD-sensitive and TCDD-resistant rat strains. Cancer Res 2000; 60: 6911-6920.
6. Fritz WA, Lin TM, Cardiff RD, Peterson RE. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 2007; 28: 497-505.
7. Fritz WA, Lin TM, Safe S, Moore RW, Peterson RE. The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-Trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol 2009; 77: 1151-1160.
8. Fritz WA, Lin TM, Peterson RE. The aryl hydrocarbon receptor (AhR) inhibits vanadateinduced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis 2008; 29: 1077-1082.
9. Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res 2010; 70: 212-220.
10. Mimura J, Yamashita K, Nakamura K, Morita M, Takagi TN, Nakao K et al. Loss of teratogenic response to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells 1997; 2: 645-654.
11. Kawajiri K, Kobayashi Y, Ohtake F, Ikuta T, Matsushima Y, Mimura J et al. Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci USA 2009; 106: 13481-13486.
12. Kolluri SK, Weiss C, Koff A, Gottlicher M. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev 1999; 13: 1742-1753.
13. Ito T, Tsukumo S, Suzuki N, Motohashi H, Yamamoto M, Fujii-Kuriyama Y et al. A constitutively active arylhydrocarbon receptor induces growth inhibition of jurkat T cells through changes in the expression of genes related to apoptosis and cell cycle arrest. J Biol Chem 2004; 279: 25204-25210.
14. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Ann Rev Pharmacol Toxicol 2003; 43: 309-334.
15. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR. Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol 2007; 71: 1475-1486.
16. Safe S, Qin C, McDougal A. Development of selective aryl hydrocarbon receptor modulators for treatment of breast cancer. Expert Opin Investig Drugs 1999; 8: 1385-1396.
17. Safe S, McDougal A. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). Int J Oncol 2002; 20: 1123-1128.
18. O'Donnell EF, Kopparapu PR, Koch DC, Jang HS, Phillips JL, Tanguay RL et al. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PloS One 2012; 7: e40926.
19. O'Donnell EF, Saili KS, Koch DC, Kopparapu PR, Farrer D, Bisson WH et al. The antiinflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS One 2010; 5: e13128.
20. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR et al. Antiestrogens. 2. Structure-Activity studies in a series of 3-Aroyl-2-Arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 1984; 27: 1057-1066.
21. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983; 32: 2869-2875.
22. Kleinberg DL, Todd J, Babitsky G. Inhibition by estradiol of the lactogenic effect of prolactin in primate mammary tissue: reversal by antiestrogens LY 156758 and tamoxifen. Proc Natl Acad Sci USA 1983; 80: 4144-4148.
23. Jordan VC. Selective estrogen receptor modulation: A personal perspective. Cancer Res 2001; 61: 5683-5687.
24. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987; 10: 31-35.
25. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-645.
26. Vogel VG. Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: The role of raloxifene. Clinical Interv Aging 2008; 3: 601-609.
27. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN et al. Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741.
28. Okamoto Y, Liu X, Suzuki N, Okamoto K, Sekimoto M, Laxmi YR et al. Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate. Int J Cancer 2008; 122: 2142-2147.
29. Barkhem T, Andersson-Ross C, Hoglund M, Nilsson S. Characterization of the 'estrogenicity' of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes. J Steroid Biochem Mol Biol 1997; 62: 53-64.
30. Kim IY, Kim BC, Seong DH, Lee DK, Seo JM, Hong YJ et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 2002; 62: 5365-5369.
31. Kim IY, Seong DH, Kim BC, Lee DK, Remaley AT, Leach F et al. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res 2002; 62: 3649-3653.
32. Stuart EC, Rosengren RJ. The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells. Life Sci 2008; 82: 943-948.
33. Bisson WH, Koch DC, O'Donnell EF, Khalil SM, Kerkvliet NI, Tanguay RL et al. Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands. J Med Chem 2009; 52: 5635-5641.
34. Denison MS, Rogers JM, Rushing SR, Jones CL, Tetangco SC, Heath-Pagliuso S. Analysis of the aryl hydrocarbon receptor (AhR) signal transduction pathway. Curr Protoc Toxicol 2002; Chapter 4: Unit 4.8.
35. Kolluri SK, Balduf C, Hofmann M, Gottlicher M. Novel target genes of the Ah (dioxin) receptor: Transcriptional induction of N-myristoyltransferase 2. Cancer Res 2001; 61: 8534-8539.
36. Weiss C, Kolluri SK, Kiefer F, Gottlicher M. Complementation of Ah receptor deficiency in hepatoma cells: negative feedback regulation and cell cycle control by the Ah receptor. Exp Cell Res 1996; 226: 154-163.
37. Wang F, Zhang R, Shi S, Hankinson O. The effect of aromatic hydrocarbon receptor on the phenotype of the Hepa 1c1c7 murine hepatoma cells in the absence of dioxin. Gene Regul Syst Biol 2007; 1: 49-56.
38. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. An online survival analysis tool to rapidly assess the effect of 22 277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 2009; 123: 725-731.
39. Mihály Z, Gyorffy B. Improving pathological assessment of breast cancer by employing array-based transcriptome analysis. Microarrays 2013; 2: 228-242.
40. Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, Gonzalez FJ. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 1996; 140: 173-179.
41. Bunger MK, Glover E, Moran SM, Walisser JA, Lahvis GP, Hsu EL et al. Abnormal liver development and resistance to 2,3,7,8-Tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-binding domain of the aryl hydrocarbon receptor. Toxicol Sci 2008; 106: 83-92.
42. Ma Q, Whitlock JP Jr. The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. Mol Cell Biol 1996; 16: 2144-2150.
43. Matthews J, Gustafsson JA. Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal 2006; 4: e016.
44. Gasiewicz TA, Henry EC, Collins LL. Expression and activity of aryl hydrocarbon receptors in development and cancer. Crit Rev Eukaryot Gene Expr 2008; 18: 279-321.
45. Hall JM, Barhoover MA, Kazmin D, McDonnell DP, Greenlee WF, Thomas RS. Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol Endocrinol 2010; 24: 359-369.
46. Goodale BC, La Du JK, Bisson WH, Janszen DB, Waters KM, Tanguay RL. AHR2 mutant reveals functional diversity of aryl hydrocarbon receptors in zebrafish. PloS One 2012; 7: e29346.
47. Khan S, Barhoumi R, Burghardt R, Liu S, Kim K, Safe S. Molecular mechanism of inhibitory aryl hydrocarbon receptor-estrogen receptor/Sp1 cross talk in breast cancer cells. Mol Endocrinol 2006; 20: 2199-2214.
48. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835-842.
49. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177: 1458-1464.
50. Taurin S, Allen KM, Scandlyn MJ, Rosengren RJ. Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression. Int J Oncol 2013; 43: 785-792.
51. Abagyan R, Totrov M, Kuznetsov D. ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J Computat Chem 1994; 15: 488-506.
52. Tosh DK, Phan K, Gao ZG, Gakh AA, Xu F, Deflorian F et al. Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. J Med Chem 2012; 55: 4297-4308.
53. Totrov M, Abagyan R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins 1997; 29(Suppl 1): 215-220.
54. Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008; 14: 285-298.
55. Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000; 289: 1159-1164.
56. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004; 116: 527-540.
57. Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W et al. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumorselective apoptosis. Proc Nat Acad Sci USA 2005; 102: 2525-2530.